SIO, a risk averse $1.4B AUM healthcare-focused hedge fund, bought after Sentinus closed their position. Every investment firm has different goals and strategies. Northwest Biotherapeutics' future growth isn't dependent upon SIO or Sentinus but imminent MHRA approval. Your post simply 💩.